Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST) Research

Scandinavian ChemoTech AB (publ) specializes in providing therapeutic options for cancer and pain management. The company's flagship product is IQWave, an advanced electroporation system. This innovative device employs brief electrical pulses in conjunction with chemotherapy, which can be administered either regionally or systemically, to treat a variety of cancers. These include specific conditions such as head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma affecting the breast and salivary gland, hypernephroma, Kaposi sarcoma, and transitional cell carcinoma. The firm markets its technologies through a network of distribution partners and influential medical professionals, primarily focusing on markets in Southeast Asia, India, and the Philippines. Founded in 2013, Scandinavian ChemoTech AB (publ) is headquartered in Lund, Sweden.

Market snapshot

Symbol
CMOTEC-B.ST
Price
$3.63
Day change
+0.55%
Market cap
$86.4M
P/E ratio
-14.30x
52-week range
1.455-7.76
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Active Biotech AB (publ) (ACTI.ST)
  • Alzinova AB (publ) (ALZ.ST)
  • Biosergen AB (BIOSGN.ST)
  • Biovica International AB (publ) (BIOVIC-B.ST)
  • Neola Medical AB (publ) (NEOLA.ST)
  • Nanologica AB (publ) (NICA.ST)
  • NextCell Pharma AB (NXTCL.ST)
  • Pila Pharma AB (publ) (PILA.ST)

Open Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.